Research programme: foetal/neonatal alloimmune thrombocytopenia therapeutic - Prophylix Pharma

Drug Profile

Research programme: foetal/neonatal alloimmune thrombocytopenia therapeutic - Prophylix Pharma

Alternative Names: anti-HPA-1a Immunoglobulin; NAITgam; Tromplate

Latest Information Update: 07 Oct 2014

Price : $50

At a glance

  • Originator Prophylix Pharma
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemolytic disease of newborn
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemolytic disease of newborn

Most Recent Events

  • 01 Oct 2014 Prophylix Pharma enters into a collaboration with New York Blood Center and BloodCenter of Wisconsin to develop the FNAIT propylaxis product
  • 30 Sep 2014 Prophylix Pharma and Emergent BioSolutions sign an agreement to manufacture the FNAIT prophylaxis therapeutic
  • 30 Apr 2012 Preclinical trials in Haemolytic disease of newborn (Prevention) in Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top